Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women …
MH Einstein, P Takacs, A Chatterjee… - Human vaccines & …, 2014 - Taylor & Francis
The observer-blind, randomized, age-stratified, head-to-head study (NCT00423046)
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy …
MH Einstein, MJ Levin, A Chatterjee… - Human vaccines & …, 2014 - Taylor & Francis
We previously reported higher anti-HPV-16 and-18 immune responses induced by HPV-
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
[HTML][HTML] Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003–2010
EY Petrosky, S Hariri, LE Markowitz, G Panicker… - International Journal of …, 2015 - Elsevier
Objective Since 2006, human papillomavirus (HPV) vaccination has been routinely
recommended for adolescent females in the USA. The quadrivalent vaccine induces long …
recommended for adolescent females in the USA. The quadrivalent vaccine induces long …
Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review
SM Tiggelaar, MJ Lin, RP Viscidi, J Ji… - Journal of Adolescent …, 2012 - Elsevier
PURPOSE: Global data on human papillomavirus (HPV) serological and deoxyribonucleic
acid (DNA) prevalence are essential to optimize HPV prophylactic vaccination strategies …
acid (DNA) prevalence are essential to optimize HPV prophylactic vaccination strategies …
[HTML][HTML] Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women
DR Brown, X Castellsagué, D Ferris, SM Garland… - Tumour Virus …, 2022 - Elsevier
Background Estimates of the humoral immune response to incident human papillomavirus
(HPV) infections are limited. Methods In this post hoc analysis of 3875 women aged 16–23 …
(HPV) infections are limited. Methods In this post hoc analysis of 3875 women aged 16–23 …
Change in human papillomavirus prevalence among US women aged 18–59 years, 2009–2014
AB Berenson, JM Hirth, M Chang - Obstetrics & Gynecology, 2017 - journals.lww.com
OBJECTIVE: To examine changes in prevalence of vaginal human papillomavirus (HPV)
between 2009–2010 and 2013–2014 among both vaccinated and unvaccinated US women …
between 2009–2010 and 2013–2014 among both vaccinated and unvaccinated US women …
[HTML][HTML] Immunogenicity and safety of two novel human papillomavirus 4-and 9-valent vaccines in Chinese women aged 20–45 years: a randomized, blinded …
Y Shu, Y Yu, Y Ji, L Zhang, Y Li, H Qin, Z Huang, Z Ou… - Vaccine, 2022 - Elsevier
Background Human papillomavirus (HPV) infections were the main cause of anogenital
cancers and warts. HPV 6/11/16/18 vaccines provide protection against the high-risk types …
cancers and warts. HPV 6/11/16/18 vaccines provide protection against the high-risk types …
Prevalence of human papillomavirus among females after vaccine introduction—National Health and Nutrition Examination Survey, United States, 2003–2014
SE Oliver, ER Unger, R Lewis… - The Journal of …, 2017 - academic.oup.com
Background Human papillomavirus (HPV) vaccine was recommended in 2006 for routine
vaccination of US females aged 11–12 years. Most vaccine used through 2014 was …
vaccination of US females aged 11–12 years. Most vaccine used through 2014 was …
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study
Z Huang, J He, J Su, Z Ou, G Liu, R Fu, Q Shou… - Vaccine, 2021 - Elsevier
Background The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was
approved for use in Chinese women aged 20–45 years in 2017. This Phase 3, open-label …
approved for use in Chinese women aged 20–45 years in 2017. This Phase 3, open-label …
Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J‐HERS 2021 multicenter study
Y Saeki, M Saito, T Irie, F Itoh, A Enatsu… - Journal of Medical …, 2024 - Wiley Online Library
This study investigated the efficacy of the prophylactic human papillomavirus (HPV) vaccine,
which was initiated between 2009 and 2013 in Japan. The study involved 1529 eligible …
which was initiated between 2009 and 2013 in Japan. The study involved 1529 eligible …